Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.
Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622),[1][2] a mitochondrial targeted compound developed to treat neurodegenerative diseases.[3][4]
In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for 120 million EUR upfront and up to 350 million EUR in milestone performance payments.[5][6] The deal was completed shortly afterwards.
Further reading
References
- T. Bordet, B. Buisson, M. Michaud, C. Drouot, P. Galea, P. Delaage, N. P. Akentieva, A. S. Evers. Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis Journal of Pharmacology and Experimental Therapeutics, 2007^
- olesoxime UKMi New Drugs Online Database, retrieved 2 January 2016^
- Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy ClinicalTrials.gov, 5 February 2010, retrieved 3 October 2010^
- Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) ClinicalTrials.gov, May 2010, retrieved 3 October 2010^
- Joshua Franklin. Roche buys France's Trophos to expand in neuromuscular disease Reuters, 16 January 2015, retrieved 30 December 2015^
- Staff. Roche to Buy Trophos for Up-to-$543M Genetic Engineering & Biotechnology News, 15 February 2015^